SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015641
Filing Date
2021-11-12
Accepted
2021-11-12 07:31:53
Documents
65
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20210930x10q.htm   iXBRL 10-Q 1922478
2 EX-31.1 akro-20210930xex31d1.htm EX-31.1 11505
3 EX-31.2 akro-20210930xex31d2.htm EX-31.2 11646
4 EX-32.1 akro-20210930xex32d1.htm EX-32.1 10860
  Complete submission text file 0001558370-21-015641.txt   6549323

Data Files

Seq Description Document Type Size
5 EX-101.SCH akro-20210930.xsd EX-101.SCH 43624
6 EX-101.CAL akro-20210930_cal.xml EX-101.CAL 38894
7 EX-101.DEF akro-20210930_def.xml EX-101.DEF 109067
8 EX-101.LAB akro-20210930_lab.xml EX-101.LAB 412097
9 EX-101.PRE akro-20210930_pre.xml EX-101.PRE 287751
10 EXTRACTED XBRL INSTANCE DOCUMENT akro-20210930x10q_htm.xml XML 1078471
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 211399594
SIC: 2834 Pharmaceutical Preparations